Main
Page 2 of 301

December 26, 2020

HAPPY HOLIDAYS 2020

We had a very quiet Christmas.  Since the pandemic first began we limited our time out of the apartment and have only seen our NYC children and grandchildren for limited times - on the sidewalk in front of our apartment, on socially distanced blankets on the grass in Central Park twice, or when they drive past to leave or pickup items.  ZOOM to the rescue!

We do have a Christmas Tree and enjoyed two full days reading and listening to classical Christmas music in the living room. next to the tree.  It was a change from our pandemic reading/TV room so it was special.  I'm posting a photo of the tree, with ornaments I made over almost 4 decades.  And I included a close-up photo of the ornament I made for this year.  I made 12 - and everyone in the family has one or will have one. 

IMG_20201218_214433264SIZE.jpg 

This ornament was made from my watercolor painting.  I cropped and sized it so I could fit 4 images onto a plastic backed 8.5 x 11" sheet of fabric which I then printed in our ink jet printer. I used 3 sheets for the 12 images and then used regular sewn techniques to make each one.  Our oldest son ran across town yesterday to pick up 8 for his and his sister's family when the rain stopped.

Virus%20Ornament.jpg

 

Wishing everyone a Happy New Year and a healthy 2021. 

December 23, 2020

The CDC Votes on a Vaccine Distribution Plan

Happy News for some of us.  CDC met this past weekend in order to establish guidelines for vaccine distribution among people in the United States.  The National Academies of Sciences, Engineering, and Medicine developed some guidelines for distribution last Fall.  The Advisory Committee on Immunization Practices (ACIP), an unrelated committee of scientists and public health experts that advises the CDC then met regularly to further refine the distribution based in part on the risk of severe infections and deaths of people in these groups. Phase 1a includes Health Care Workers and staff and patients in Long Term Care Facilities.  Both of these groups just began vaccinations under the guidance of the their states. 

Last weekend the committee met to finalize their recommendations for the next Phase of vaccinations.  Their decisions were based on which groups had the next highest risk of serious infections and deaths. After extensive discussions among committee members, and an open session in which other speakers were able to present their opinions, the committee approved Phases 1b and 1c. These are recommendations for the jurisdictions (states/territories) to set up programs for vaccinations.  We are very happy with the guidelines adopted.   See Below 

Group1bSIZE.jpg 

Phase 1b

People 75 years and older and non-health care essential workers (approximately 49 million people).

Phase 1c

People between 65 and 74 years of age and people 16-64 years with comorbidities, and essential workers not covered in Phase 1b: first responders (fireman, police, corrections officers, food and agriculture workers, US Postal Service workers, manufacturing workers (like those making medications) grocery store workers, public transit workers and those who work in education and child care. 

My husband and I are happy that we moved up in the vaccination schedule.  We are in the high risk >75 years group and we have severely limited our activities and contacts since the pandemic began.  Once vaccinated we will still wear masks and follow all of the public health recommendations, but at least we have something to look forward to - in person visits with our children and grandchildren. 

https://www.cdc.gov/mmwr/volumes/69/wr/mm695152e2.htm?s_cid=mm695152e2_w 

 

December 19, 2020

The Moderna Vaccine Application for EUA

The Moderna Vaccine, developed by the Massachusetts Company in collaboration with Dr. Fauci's Institute at NIH, was approved by the FDA last evening.

On Thursday I watched the FDA Vaccine Related Biologics Products Advisory Committee Meeting, during which 21 independent scientific committee members heard 2 presentations: (1) by Moderna with detailed information from their Phase 3 Clinical Trial (30,420 volunteers) and (2) the FDA who presented their summary by the more than 100 FDA Career Scientists' of the Moderna Trial data.  In order to approve a product with an Emergency Use Authorization (EUA) there needs to be a catastrophic public health emergency, and no licensed product to treat people.  The drug companies need to submit an enormous amount of data from their phase 3 clinical trials and after scientific review by independent committees and the FDA, approval can be granted if the benefits outweigh the risks.  The committee voted 20 to 0 to recommend an emergency use authorization (EUA), and the FDA usually follows their guidance.  There are many studies yet to be done to examine the immune response and duration, and virus transmission in infected subjects.  The FDA EUA was granted and the vaccine will be shipped.    See Below

ModernaEUASIZE.jpg 

The Moderna efficacy in preventing symptomatic Covid-19 was 94% for different age, ethnic, and racial groups.  The vaccine also prevented severe covid-19 with 0 cases in the vaccine group and 30 in the placebo group. At least 50% of the enrolled volunteers were followed for more than 2 months and the side effects were almost all mild to moderate - with fever, pain, swelling, and redness at the injection site, headache, chills, fatigue, muscle and joint aches following the vaccination. Patients should be aware of these symptoms. Some of the same symptoms occurred in the placebo group at a lower incidence - which always surprises me! Symptoms increased after the second dose but were gone after several days.  There were 4 cases of Bell's palsy, in which the facial nerve, on one side of the face, is affected, but recovers slowly.  There was one case in the placebo group and 3 in the vaccinated group.  The incidence will be followed closely to see if turns out to be more frequent than the spontaneous incidence in the general population.  There were no allergy symptoms or anaphylaxis seen.  The vaccine needs to be stored at only -4 degrees C.and can be maintained in the refrigerator for 30 days - making it easier to transport and store.   

 

December 16, 2020

What is Operation Warp Speed?

When the coronavirus SARS-CoV-2 was identified last year scientists knew that vaccines needed to be developed and many companies and research facilities began the process (more than 150).  The fastest a vaccine has ever been developed is 4 years - the mumps vaccine.  Suddenly a pandemic was declared and a worldwide catastrophe was imminent.  By early April Dr. Peter Marks, an oncologist who worked in academia and the drug industry and was currently the head of the FDA division that regulates vaccines, began laying the groundwork for what would become Operation Warp Speed.  Working with Robert Kadlec he wrote a proposal for the HHS Sec'y Alex Azar for a process that went from screening potential vaccine candidates to distributing the final product to 330 million Americans. Dr.Marks was a longtime Star Trek Fan and dubbed the proposal Operation Warp Speed.   

They wanted to find 8 vaccines that were promising in early testing, and select 2 for each method of vaccine development.  The first 5 companies that were selected were Moderna, Oxford-AstraZeneca, Johnson and Johnson, Merck, and Sanofi Glaxo Smith Kline.  Pfizer didn't accept government funds for vaccine development, but signed a contract with the government to buy 100 million doses of their vaccine if successful.  Novavax and Vaxart were accepted later.  Operation Warp Speed was announced on May 15th and vaccine development became a private-public partnership with gov't financial support. Government funding also allowed the companies to begin manufacturing, which is a financial risk if the vaccines aren't successful.    Read Below  

OWSSIZE.jpg 

All drugs and vaccines go through preclinical, Phase 1, 2, and 3 Clinical Trials.  Phase 3 clinical trials randomize volunteers between vaccine and placebo to determine efficacy in preventing Covid-19 and safety.  In Operation Warp Speed, every company had to have 30,000-50,000 trial subjects to make sure that the results were statistically significant. Pfizer and Moderna had very successful Phase 3 Trials and both should have an Emergency Use Authorization within days.  Developing vaccines can be very frustrating and both Oxford-AstraZeneca and Sanofi-GSK have hit some problems.  Oxford-Astrazenca's trial inadvertently used half the amount of vaccine for the first dose in a portion of their trial participants (~3000), which actually showed higher efficacy than the 2 full dose vaccinations.  They now need to test these varying doses and add additional trial volunteers in order to determine if the efficacy continues to be 90%. Sanofi's vaccine was not as effective in older volunteers and the vaccine will be revised and retested in older subjects.  We should soon be hearing about clinical trials from the other 4, especially J and J and Merck.

 

December 12, 2020

The Pfizer BioNTech SARS-CoV-2 Vaccine Receives an EUA

On Dec 10th the Vaccine and Related Biologic Products scientific Advisory Committee (VRBPAC) met virtually with the FDA Vaccine Group for 7 presentations and Q and A sessions.  Many FDA scientists analyzed hundreds of pages of data about the Pfizer BioNTech vaccine since Pfizer applied for an EUA in early November.  Their review was then summarized in a 53 page document which is available on the FDA site.  An Emergency Use Authorization (EUA) can be granted if there is a public health catastrophe and there is no licensed treatment.  There were more than 43,000 clinical subjects in the Pfizer Clinical Trial, half were vaccinated and half received saline placebo. The efficacy of the vaccine was 95% in both sexes, all ages, and racial/ethnic groups, and it appears as if an immune response appeared as early as day 12 after the first dose.  The major safety issues occur in the first 1-2 days after the vaccine injection and include flu-like symptoms that are mild to moderate.  Four vaccinated volunteers developed a Bell's palsy, but it is unclear that this is a higher incidence than in the general population.  When study subjects have been followed for 6 months, the EUA could be converted to a Biologic License Approval based on reassessment of the data. 

It is very comforting to see how many academic scientists have analyzed all of the data - both the advisory committee members and as career scientists at the FDA.  There are still limitations fo this vaccine - pregnant women and children younger than 16 have not been included in the clinical trials and now need to be tested separately.   Read Below. 

PfizerEUASIZE.jpg

Two nurses had an acute allergic reaction on the first day of the vaccinations in the UK.  Both had a history of severe allergies and carried an EpiPen.   These reactions could be due to allergies to food, drugs, or vaccines and Pfizer is collecting as much information about them as possible.  It is comforting to know that severe food allergies, like peanuts and eggs, did not disqualify people from being part of the clinical trial and no allergic reactions were seen.  For now, they are recommending that anyone with severe allergies delay their injections until all of the information is assessed.  Both women were treated and recovered completely - at least one of them with epi-pen and steroids, but not disclosed for the other one.  

 

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301